Lorlatinib Continuation Study (NCT05144997)

🧪 Interventions in This Study

• Lorlatinib (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. 1 - Any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study. 2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (27 Sites)

Showing the first 25 of 27 sites.

• Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• The First affiliated Hospital of Anhui Medical University — Hefei, Anhui
• Beijing Chest Hospital, Capital Medical University — Beijing, Beijing Municipality
• Beijing Cancer Hospital — Beijing, Beijing Municipality
• Fujian Cancer Hospital — Fuzhou, Fujian
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong
• Hunan Provincial Tumor Hospital — Changsha, Hunan
• General Hospital of Eastern Theater Command — Nanjing, Jiangsu
• Jilin Cancer Hospital — Changchun, Jilin
• The first hospital of jilin university — Changchun, Jilin
• Sir Run Shaw Hospital — Hangzhou, Qiantang District
• The Second Affiliated Hospital of PLA Air Force Medical University — Xi'an, Shaanxi
• Shanghai Chest Hospital — Shanghai, Shanghai Municipality
• Sichuan Cancer hospital — Chengdu, Sichuan
• The First Affiliated Hospital Zhejiang University School of Medicine — Hangzhou, Zhejiang
• Zhejiang Cancer Hospital — Hangzhou, Zhejiang
• The Second Affiliated Hospital of Zhejiang University College of Medicine — Hangzhou, Zhejiang
• Fudan University Shanghai Cancer Center — Shanghai,
• CHU de Rennes - Hôpital Pontchaillou — Rennes,
• Institut Gustave Roussy — Villejuif,
• Healthcare Global Enterprises — Bengaluru, Karnataka
• Bhaktivedanta Hospital & Research Institute — Thane, Maharashtra
• Aichi Cancer Center Hospital — Nagoya, Aichi-ken
• National University Hospital — Singapore,
• National Cancer Centre Singapore — Singapore,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Small-Cell Lung Cancer

• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — Fullerton, California
• Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer — Duarte, California

Explore by condition: All Non-Small-Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.